

Synthesis and *in vitro* antiproliferative activity of new benzothiazole derivatives

Yaseen A. Al-Soud,¹ Haitham H. Al-Sa'doni,¹ Bahjat Saeed,² Ihsan H. Jaber,¹
Mohammad O. Beni-Khalid,¹ Najim A. Al-Masoudi,^{3,*} Tahsin Abdul-Kadir,² Paolo La
Colla,⁴ Bernardetta Busonera,⁴ Tiziana Sanna,⁴ and Roberta Loddo⁴

¹ Department of Chemistry, College of Science, University of Al al-Bayt, Al-Mafraq, Jordan

² Department of Chemistry, College of Education, University of Basrah, Basrah, Iraq

³ Fachbereich Chemie, Universität Konstanz, Postfach 5560, D-78457 Konstanz, Germany,
(Formerly)

⁴ Department of Biomedical Sciences and Technologies, University of Cagliari, Cittadella
Universitaria, 09042 Monserrato (CA), Italy

E-mail: Najim.Al-Masoudi@gmx.de

Abstract


A series of benzothiazole bearing piperazino-arylsulfonamides (**5a-k**), and arylthiol analogues (**6a-j**) as well as substituted benzothiazoles having sulfonamides (**9b**, **9l-n** and **10**) have been synthesized. All compounds were evaluated, *in vitro*, for their antiproliferative activity against a large panel of human tumor-derived cell lines. Compounds **5c**, **5d**, **5j**, **6b**, **6c** and **6j** were the most potent analogues in this series, showing activity against both cell lines derived from haematological and solid tumors (CC₅₀ range = 8-24 μ M), only **5d** was found to be selective and not cytotoxic to normal human tissues.

Keywords: Antiproliferative activity, arylthiols, benzothiazoles, sulfonamides

Introduction

A number of benzothiadiazoles showed selective antiproliferative activity, especially the phenyl-substituted benzothiazoles,¹⁻³ while condensed pyrimido benzothiazoles and benzothiazolo quinazolines exert antiviral activity.⁴ Substituted 2-(4-aminophenyl)benzothiazoles were developed and examined, *in vitro*, for their antiproliferative activity in ovarian, breast, renal and colon carcinoma human cell lines,⁵⁻⁸ imidazo benzothiazoles,^{9,10} as well as, polymerized benzothiazoles¹¹ and other substituted benzothiazoles¹² showed remarkable antitumor activity against malignant cell lines. The aryl amines, 2-(4-amino-3-methylphenyl)benzothiazole,^{13,14} 2-

(4-aminophenyl)-benzothiazole,¹⁵ the fluoro analogue (5F 203),¹⁶ 2-(3,4-dimethoxyphenyl)-5-fluoro-benzothiazole (**1**)¹⁷ are considered as potent ligands for the arylhydrocarbon receptor (AhR) which translocates with the drug to cell nuclei. A further class of benzothiazoles have been synthesized and exhibited potent antitumor activity *e.g.* benzothiazole-substituted 4-hydroxycyclohexadieneone¹⁸ against renal, colon cancer cell lines and prodrug Phortress,¹⁹ human mammary tumor xenografts,²⁰ and is currently under the pharmacological investigation in phase I clinical trial in the UK. Yoshida *et al.*²¹ have synthesized a highly potent benzothiazole derivative bearing an amido with that displays excellent *in vivo* inhibitory effect on tumor growth. Recently, Racane *et al.*²² have described the synthesis of bis-disubstituted amidino benzothiazoles as potential anti HIV agents.




Although the nature of the 2-substituent of benzothiazole backbone (*e.g.* aryl group in **1**) exerts a profound influence on the predominant biotransformation pathway as well as the focus of preclinical interest, but introduction of potential substituents at C-2, such as 4-arylthio piperazine residues, might optimizing the antiproliferative activity and then explain the mechanism of action in comparison with other classes of chemotherapeutic agent or carcinogenic aromatic amines. We report here antiproliferative evaluation of new benzothiazole derivatives bearing (piperazinyl-1-yl)-2-(arylthio)-ethanone for antitumor activity.

Results and Discussion


Our recent work had focused on preparation of 2-amino-1-(4-(benzo[*d*]thiazol-2-yl)piperazin-1-yl)ethanone (**4**),²³ which was prepared from **2**²⁴ *via* the chloro derivative **3**,²³ as starting material for the synthesis of potentially active analogues. In the present work, amine **4** has been selected for the synthesis of new potentially active substituted sulfonamide derivatives. Thus, reaction of **4** with the arylsulphonyl chloride: benzene-, *p*-toulene-, 4-chlorobenzene-, 2,5-dichlorobenzene-, 4-nitrobenzene-, 3-trifluoromethylbenzene-, 4-methoxybenzene-, 8-quinolin-, 2-thiophene-, 2,5-dichlorothiophene- and 3-bromo-5-chlorothiophene sulfonyl chlorides afforded the corresponding sulfonamide products **5a-k** in 90-96% yield (Scheme 1).

The structures of the newly synthesized compounds **5a-k** were assigned by the ¹H, ¹³C NMR, MS which are in agreement with the suggested structures. DEPT experiments were employed to differentiate secondary and quaternary from primary and tertiary carbons.




Scheme 1. Reagents and conditions: (i) 2-Chloroacetyl chloride, Et₃N, 23 °C, CH₂Cl₂, 3 h; (ii) potassium phthalimide, DMF, 120-130 °C, 24 h; (iii) NH₂NH₂.H₂O, reflux, 4 h; (iv) ArSO₂Cl, Et₃N, CH₂Cl₂, 23 °C, 20 h

Additional models of benzothiazole derivatives bearing keto substituted piperazine residues were prepared. Thus, treatment of **3** with aryl thiols: thiophenol, pyridine-2-thiol, 4-methylpyrimidine-2-thiol, 5-methyl-1,3,4-thiadiazole-2-thiol, 1,2,3-triazole-5-thiol, 1-methylimidazole-2-thiol, 1-phenyl-tetrazole-5-thiol, benzo[*d*]oxazole-2-thiol, benzo[*d*]thiazole-2-thiol and benzo[*d*]imidazole-2-thiol in the presence of NaH at 23 °C afforded **6a-j** in 33-86% yield (Scheme 2). The assignment of protons and carbons of the benzothiazole ring and piperazine were deduced from comparison with compounds **5a-k**. The CH₂S protons resonated at δ 4.02-4.45 ppm as a singlet. In the ¹³C NMR spectra of **6a-j**, CH₂S carbon appeared at the region δ 31.8-37.1 ppm. Resonances at δ 24.2, 15.7 and 33.5 ppm were assigned to the CH₃ carbons of **6c**, **6d** and **6f**, respectively. The higher-field resonances at the region δ 168.0-170.0 ppm were attributed to the carbonyl. The carbons of aromatic, pyridine, pyrimidine, thiazole, triazole, imidazole, tetrazole, benzoxazole, benzothiazole, and benzoimidazole conjugated to CH₂S group were assigned.

**Scheme 2**

Further, our work was modified by selecting the 5-ethoxybenzo[d]thiazol-2-amine (**7**) and its 6-iodo analogue **8** as precursors for the synthesis of new derivatives to examine their antitumor activity in comparison to the sulfonamide analogues **5a-k** and **6a-j**. Compounds **9b**, **9l-n** and **10** were prepared in 76, 77, 57, 60 and 70% yields, respectively from **7** and **8** by applying the sulfonylation method used previously in the preparation of **5a-k** (Scheme 3). The structures of **9b**, **9l-n** and **10** were confirmed by their ^1H NMR, ^{13}C and mass spectra.

**Scheme 3.** Reagents and conditions: (i) RSO_2Cl , Et_3N , CH_2Cl_2 , $23\text{ }^\circ\text{C}$, 20 h

***In vitro* antiproliferative activity**

Compounds **5a-k**, **6a-j**, **9b**, **9l-n** and **10** were tested, *in vitro*, against a large panel of human cell lines derived from hematological [CD4⁺ human T-cells containing an integrated HTLV-1 genome (MT-4); CD4⁺ human acute T-lymphoblastic leukaemia (CCRF-CEM); Human splenic B-lymphoblastoid cells (WIL-2NS); Human acute B-lymphoblastic leukemia (CCRF-SB)] and solid [skin melanoma (SK-28); breast adenocarcinoma (MCF-7); lung squamous carcinoma (SK-MES-1); hepatocellular carcinoma (HepG-2); prostate carcinoma (DU-145)] or normal tissues [lung fibroblasts (MRC-5)].

For comparative purposes, we evaluated the cytotoxic activities of the compounds relative to Doxorubicin. As shown in Table 1, the benchmark active compounds were **5c** especially against the human prostate carcinoma (DU-145) cell lines ($CC_{50} = 8 \pm 3 \mu\text{M}$) and **5d** against the human hepatocellular carcinoma (HepG2) and human prostate (DU-145) cell lines ($CC_{50} = 8 \pm 2 \mu\text{M}$, $9 \pm 2 \mu\text{M}$, respectively).

Introduction of a chloro-, dichlorophenyl and dichlorothiophene residues in the backbones of **5c**, **5d** and **5j**, generally enhanced the potency: dramatic changes in activity were observed with the other congeners (compounds **5a,b**, **5e-i**, **5k**). Thus, replacement of either (or both) of the chloro groups by hydrogen (**5a**), methyl (**5b**), nitro (**5e**), trifluoromethyl (**5f**), or methoxy (**5g**) substituents had a deactivating effect. Similarly, the analogues **5h**, **5i** and **5k** having congeners other than chloro substituent showed only low micromolar inhibitory potency.

All of the piprazino-arylthio analogues (**6a-j**) were found to be markedly less active against the cancer cell lines tested when compared to the lead compound **5c**, **5d** and **5i**, except **6c** and **6j**, which exhibited activity against both cell lines derived from haematological and solid tumors.

The metabolic biotransformation of **5b**, **5c** and **5d** in human cells might be mediated through the CYP1 family of cytochrome P450s.²⁶

Compounds **9b**, **9l-n** and **10** were found to be inactive against all panels of tumor cell lines ($CC_{50} > 100 \mu\text{M}$), data not shown.

Table 1. Antiproliferative activity against haematological and solid human tumor cell lines and “normal human tissues”

| Entry | CC ₅₀ (μM) ^a | | | | | | | | | |
|---------------------------|------------------------------------|-----------------------|----------------------|----------------------|------------------------|-------------------|-----------------------|--------------------|--------------------|--------------------|
| | MT-4 ^a | CCRF-CEM ^b | WIL-2NS ^c | CCRF-SB ^d | SK-MEL-28 ^e | MCF7 ^f | SK-MES-1 ^g | HepG2 ^h | DU145 ⁱ | MRC-5 ^j |
| 5a | >100 | >100 | >100 | 82±18 | >100 | 29±2 | 24±2 | 24±1 | 18±3 | 66±7 |
| 5b | 58±2 | 28±5 | 94±6 | 25±7 | 23±3 | 23±0.5 | 21±4 | 26±2 | 18±1 | >100 |
| 5c | >100 | 13±4 | 16±4 | 14±0.5 | 11±1 | 10±2 | 12±0.5 | 10±0.5 | 8±3 | 17±2 |
| 5d | 16±1 | 12±0.5 | 24±0.6 | 17±5 | 21±3 | 13±0.05 | 18±2 | 8±2 | 9±2 | >100 |
| 5e | >100 | >100 | 82±10 | 18±1 | 84±16 | 90±10 | 52±6 | 61±2 | 18±2 | >100 |
| 5f | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 5g | 44±5 | 30±6 | 91±5 | 32±4 | >100 | 33±5 | 29±2 | 38±2 | 28±2 | >100 |
| 5h | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 5i | 33±3 | 39±8 | 25±4 | 23±5 | >100 | 22±0.5 | 29±4 | 23±0.1 | 17±3 | >100 |
| 5j | 22±2 | 13±1 | 14±1 | 23±1 | 13±0.5 | 17±4 | 12±0.8 | 13±1 | 11±1 | 16±1 |
| 5k | 29±3 | 21±0.7 | >100 | >100 | >100 | >100 | >100 | >100 | 14±2 | 82±18 |
| 6a | >100 | 91±10 | >100 | 84±8 | 90±10 | >100 | >100 | >100 | 40±5 | 100 |
| 6b | 74±6 | 36±3 | 60±9 | 24±4 | 35±8 | 52±2 | 34±4 | 23±3 | 26±4 | 40±10 |
| 6c | 46±4 | 12±2 | 13±2 | 13±0.5 | 18±3 | 14±2 | 19±0.5 | 17±2 | 17±1.5 | 24±4 |
| 6d | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 6e | >100 | 16±6 | 50±10 | ≥100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 6f | 79±9 | 39±0.1 | 85±15 | 80±20 | 38±1 | 61±1 | 32±0.3 | 34±5 | 25±2 | 62 |
| 6g | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 6h | >100 | 74±5 | >100 | 61±9 | 75±8 | 87±13 | 80±20 | 73±3 | 67±13 | 80±10 |
| 6i | 40±2 | 21±4 | 46±12 | 30±6 | ≥100 | >100 | 90±6 | >100 | 80±20 | >100 |
| 6j | >100 | 17±2 | 19±1.5 | 29±9 | 19±1.5 | 17±3 | 19±1 | 13±0.2 | 14±3 | >100 |
| Doxorub-Icin ^k | 0.01 | 0.02 | 0.02 | 0.03 | | | | | | |

^a Compound concentration required to reduce cell proliferation by 50%, as determined by the MTT method, under conditions allowing untreated controls to undergo at least three consecutive rounds of multiplication. Data represent mean values (±SD) for three independent determinations. ^a CD4⁺ human T-cells containing an integrated HTLV-1 genome. ^b CD4⁺ human acute T-lymphoblastic leukaemia. ^c human splenic B-lymphoblastoid cells ^d human acute B-lymphoblastic. ^e human skin melanoma. ^f human breast adenocarcinoma. ^g human lung squamous carcinoma. ^h human hepatocellular carcinoma. ⁱ human prostate carcinoma. ^j human lung fibroblasts. ^k control.

In conclusion, we report the synthesis and *in vitro* biological evaluation of new benzothiazole derivatives as potential cytotoxic agents. The first results confirm the identification of the chlorinated-arylsulphonamide *N*-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxoethyl) structure as a new antiproliferative pharmacophore, with the 4-chloro and 2,5-dichlorophenylsulphonamide or 2,5-dichlorothiophene analogues (**5c**, **5d** and **5j**) being the agents of choice for further pharmacological evaluation. Further experiments aimed at defining the target and the mechanisms of the inhibitory effect showed by these molecules are in progress and the results will be reported in a forthcoming paper.

Experimental Section

General Procedures. Melting points are uncorrected and were measured on a Büchi melting point apparatus B-545 (Büchi Labortechnik AG, Switzerland). Microanalytical data were obtained with a Vario, Elemental apparatus (Shimadzu, Japan). NMR spectra were recorded on 300 MHz (^1H) and on 75 MHz (^{13}C) spectrometers (Bruker, Germany) with TMS as internal standard and on the δ scale in ppm. Mass spectra were recorded at 70 eV on EI. Silica gel (0.040–0.063 mm) used for column chromatography and analytical silica gel TLC plates 60 F254 were purchased from Merck.

General procedure for the preparation of *N*-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxoethyl)arylsulfonamides (**5a-k**)

A solution of **4** (1.00 mmol) and an arylsulfonyl chloride (**a-k**) (1.00 mmol) in CH_2Cl_2 (50 mL) containing Et_3N (0.1 mL, 1.00 mmol) was stirred at 23 °C for 20 h. The solvent was evaporated to dryness and the residue was purified on thin layer chromatography, using CHCl_3 -MeOH (30:1) as eluent to give the desired product, which recrystallized from EtOH.

***N*-(2-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)benzenesulfonamide (**5a**).** From **a** (0.18 g). Yield: 0.39 g (93%); mp 175-177 °C. ^1H NMR ($\text{DMSO-}d_6$): δ 3.52 (brs., 8H, $H_{\text{piperazine}}$); 3.82 (s, 2H, $\text{CH}_2\text{C=O}$); 7.08-7.61 (m, 9H, H_{arom}), 7.63 (brs., 1H, NH). ^{13}C NMR ($\text{DMSO-}d_6$): δ 41.1 (NHCH₂); 43.9, 44.4, 47.9, 48.2 ($C_{\text{piperazine}}$); 119.1, 121.9, 126.5, 127.1, 129.5, 130.9, 132.9 (C_{arom}); 140.9 ($C_{\text{arom-SO}_2}$); 152.7 ($C^{3a}_{\text{benzothiazole}}$); 166.4 (C=O); 168.5 (C=N). Anal. calcd. for $\text{C}_{19}\text{H}_{20}\text{N}_4\text{O}_3\text{S}_2$: C, 56.50; H, 5.84; N, 20.27. Found: C, 56.28; H, 5.92; N, 20.48. m/z (EI) 416 (M^+).

***N*-(2-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-4-methylbenzenesulfonamide (**5b**).** From **b** (0.19 g). Yield: 0.40 g (94%); mp 180-183 °C. ^1H NMR (CDCl_3): δ 2.43 (s, 3H, CH_3); 3.52-3.76 (m, 8H, $H_{\text{piperazine}}$); 3.81 (s, 2H, $\text{CH}_2\text{C=O}$); 5.66 (brs., 1H, NH); 7.33 (d, $J = 7.8$ Hz, 2H, H_{arom}); 7.35-7.65 (m, 4H, H_{arom}); 7.78 (d, $J = 7.8$ Hz, 2H, H_{arom}). ^{13}C NMR (CDCl_3): δ 21.4 (CH_3); 41.2 (NHCH₂); 43.9, 47.2, 48.0, 48.1 ($C_{\text{piperazine}}$); 118.9, 121.9, 122.1, 126.7, 129.9, 130.4 (C_{arom}); 137.9 ($C_{\text{arom-SO}_2}$); 143.1 ($C^4_{\text{arom-Me}}$); 151.9 ($C^{3a}_{\text{benzothiazole}}$); 166.5 (C=O); 168.5

(C=N). Anal. calcd. for C₂₀H₂₂N₄O₃S₂: C, 55.79; H, 5.15; N, 13.01. Found: C, 55.92; H, 4.97; N, 13.11. *m/z* (EI) 430 (M)⁺.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-4-chlorobenzenesulfonamide**

(5c). From **c** (0.21 g). Yield: 0.42 g (94%); mp 165-167 °C. ¹H NMR (DMSO-*d*₆): δ 3.52 (brs., 8H, *H*_{piperazine}); 3.85 (s, 2H, CH₂C=O); 7.06-7.48 (m, 3H, *H*_{arom}), 7.65 (d, *J* = 7.0 Hz, 2H, *H*_{arom}); 7.76 (d, *J* = 6.8 Hz, 1H, *H*_{arom}); 7.84 (d, *J* = 7.0 Hz, 2H, *H*_{arom}); 7.93 (brs., 1H, NH). ¹³C NMR (DMSO-*d*₆): δ 41.2 (NHCH₂); 41.9, 44.3, 48.0, 48.2 (*C*_{piperazine}); 119.2, 121.3, 121.9, 126.5, 129.1, 129.6, 130.9 (*C*_{arom}); 139.9 (*C*⁴_{arom-Cl}); 142.0 (*C*_{arom-SO₂}); 152.7 (*C*^{3a}_{benzothiazole}); 166.4 (C=O); 168.5 (C=N). Anal. calcd. for C₁₉H₁₉ClN₄O₃S₂: C, 50.60; H, 4.25; N, 12.42. Found: C, 50.81; H, 4.50; N, 12.30. *m/z* (EI) 450/452.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-2,5-dichlorobenzenesulfonamide**

(5d). From **d** (0.25 g). Yield: 0.46 g (95%); mp 156-159 °C. ¹H NMR (DMSO-*d*₆): δ 3.52 (br s., 8H, *H*_{piperazine}); 4.04 (s, 2H, CH₂C=O); 7.08-7.98 (m, 7H, *H*_{arom}), 8.12 (brs, 1H, NH). ¹³C NMR (DMSO-*d*₆): 41.2 (NHCH₂); 43.9, 44.7, 48.0, 48.2 (*C*_{piperazine}); 119.2, 121.1, 126.5, 129.9, 130.2, 130.9, 132.2 (*C*_{arom}); 133.8 (*C*²_{arom-Cl}), 140.6 (*C*⁴_{arom-Cl}); 152.7 (*C*^{3a}_{benzothiazole}); 166.6 (C=O); 168.5 (C=N). Anal. calcd. for C₁₉H₁₈Cl₂N₄O₃S₂: C, 47.01; H, 3.74; N, 11.54. Found: C, 46.88; H, 3.90; N, 11.76. *m/z* (EI) 484/486 (M)⁺.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-4-nitrobenzenesulfonamide (5e).**

From **e** (0.22 g). Yield: 0.44 g (96%); mp 182-185 °C. ¹H NMR (DMSO-*d*₆): δ 3.51 (brs., 8H, *H*_{piperazine}); 3.95 (s, 2H, CH₂C=O); 7.06-7.80 (m, 4H, *H*_{arom}), 8.09 (d, *J* = 7.0 Hz, 2H, *H*_{arom}); 8.26 (br s., 1H, NH); 8.39 (d, *J* = 7.0 Hz, 2H, *H*_{arom}). ¹³C NMR (DMSO-*d*₆): δ 41.2 (NHCH₂); 43.9, 44.4, 48.0, 48.2 (*C*_{piperazine}); 119.2, 121.7, 121.9, 124.8, 126.5, 128.7, 130.9 (*C*_{arom}); 146.8 (*C*²_{arom-NO₂}); 149.9 (*C*_{arom-SO₂}); 152.7 (*C*^{3a}_{benzothiazole}); 166.3 (C=O); 168.5 (C=N). Anal. calcd. for C₁₉H₁₉N₅O₅S₂: C, 49.45; H, 4.15; N, 15.17. Found: C, 49.30; H, 4.22; N, 15.43. *m/z* (EI) 461 (M)⁺.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-3-(trifluoromethyl)benzenesulfonamide (5f).**

From **f** (0.24 g). Yield: 0.44 g (91%); mp 194-196 °C. ¹H NMR (DMSO-*d*₆): δ 3.52 (brs., 8H, *H*_{piperazine}); 3.93 (s, 2H, CH₂C=O); 7.08-8.03 (m, 8H, *H*_{arom}), 8.15 (br s., 1H, NH). ¹³C NMR (DMSO-*d*₆): 41.2 (NHCH₂); 43.9, 44.4, 48.0, 48.2 (*C*_{piperazine}); 119.2, 121.7, 121.9, 123.9, 126.5, 129.4, 129.5, 129.9, 130.9, 131.0, 131.2 (*C*_{arom} + CF₃); 142.4 (*C*_{arom} + SO₂); 152.7 (*C*^{3a}_{benzothiazole}); 166.3 (C=O); 168.5 (C=N). Anal. calcd. for C₂₀H₁₉F₃N₄O₃S₂: C, 49.58; H, 3.95; N, 11.65. Found: C, 49.74; H, 4.18; N, 11.75. *m/z* (EI) 483/485 (M)⁺.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-4-methoxybenzenesulfonamide**

(5g). From **g** (0.21 g). Yield: 0.49 g (91%); mp 150-152 °C. ¹H NMR (DMSO-*d*₆): δ 3.53 (brs., 8H, *H*_{piperazine}); 3.77 (s, 2H, CH₂C=O); 3.81 (s, 3H, OCH₃); 7.09 (d, *J* = 7.0 Hz, 2H, *H*_{arom}); 7.26-7.49 (m, 4H, *H*_{arom}); 7.58 (s, 1H, NH); 7.77 (d, *J* = 7.0 Hz, 2H, *H*_{arom}). ¹³C NMR (DMSO-*d*₆): δ 41.2 (NHCH₂); 44.0, 44.5, 48.0, 48.2 (*C*_{piperazine}); 56.1 (OCH₃); 114.7, 119.2, 121.7, 121.9, 126.5, 129.4, 130.9, 132.4 (*C*_{arom}); 152.7 (*C*^{3a}_{benzothiazole}); 162.6 (*C*_{arom-OMe}); 166.5 (C=O); 168.5 (C=N). Anal. calcd. for C₂₀H₂₂N₄O₄S₂: C, 53.79; H, 4.97; N, 12.55. Found: C, 53.51; H, 4.84; N, 12.49. *m/z* (EI) 446 (M)⁺.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)quinoline-8-sulfonamide (5h).** From **h** (0.23 g). Yield: 0.42 g (90%); mp 205-208 °C. ¹H NMR (DMSO-*d*₆): δ 3.44 (brs., 8H, *H*_{piperazine}); 3.53 (s, 2H, CH₂C=O); 7.07-8.57 (m, 9H, *H*_{arom} + NH); 9.08 (d, 1H, *J* = 5.0 Hz, *H*²_{quinolin}). ¹³C NMR (DMSO-*d*₆): δ 41.1 (NHCH₂); 43.6, 44.8, 47.9, 48.0 (*C*_{piperazine}); 119.2, 121.7, 121.9, 123.0, 126.2, 126.5, 129.0, 130.8, 131.0, 134.2, 136.3, 137.6 (*C*_{arom} + *C*_{quinolin}); 143.2 (*C*^{8a}_{quinolin}); 151.8 (*C*²_{quinolin}); 152.7 (*C*^{3a}_{benzothiazole}); 166.4 (C=O); 168.4 (C=N). Anal. calcd. for C₂₂H₂₁N₅O₃S₂: C, 56.51; H, 4.53; N, 14.98. Found: C, 56.80; H, 4.44; N, 14.67. *m/z* (EI) 467 (M)⁺.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)thiophene-2-sulfonamide (5i).** From **i** (0.18 g). Yield: 0.41 g (96%); mp 115-118 °C. ¹H NMR (DMSO-*d*₆): δ 3.35 (brs., 8H, *H*_{piperazine}); 3.90 (s, 2H, CH₂C=O); 7.06-7.93 (m, 7H, *H*_{arom}); 8.02 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ 41.2 (NHCH₂); 44.0, 44.6, 48.0, 48.3 (*C*_{piperazine}); 119.1, 121.8, 121.9, 126.5, 128.1, 130.7, 132.3, 133.0, 141.6 (*C*_{arom} + *C*_{thiophene}); 152.5 (*C*^{3a}_{benzothiazole}); 166.3 (C=O); 168.5 (C=N). Anal. calcd. for C₁₇H₁₈N₄O₃S₃: C, 48.32; H, 4.29; N, 13.26. Found: C, 48.46; H, 4.05; N, 13.11. *m/z* (EI) 422 (M)⁺.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-2,5-dichlorothiophene-3-sulfonamide (5j).** From **j** (0.25 g). Yield: 0.46 g (94%); m.p. 120-122 °C. ¹H NMR (DMSO-*d*₆): δ 3.56 (brs., 8H, *H*_{piperazine}); 4.04 (s, 2H, CH₂C=O); 7.06-7.31 (m, 2H, *H*_{arom}); 7.36 (s, 1H, *H*_{thiophene}); 7.47 (d, *J* = 8 Hz, 1H, *H*_{arom}); 7.78 (d, *J* = 8 Hz, 1H, *H*_{arom}); 8.25 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ 41.3 (NHCH₂); 43.9, 44.1, 48.0, 48.2 (*C*_{piperazine}); 119.2, 121.7, 122.0, 126.2, 126.6, 127.4, 129.2, 130.8, 137.6 (*C*_{arom} + *C*_{thiophene}); 152.6 (*C*^{3a}_{benzothiazole}); 166.4 (C=O); 168.6 (C=N). Anal. calcd. for C₁₇H₁₆Cl₂N₄O₃S₃: C, 41.55; H, 3.28; N, 11.40. Found: C, 41.27; H, 3.46; N, 11.27. *m/z* (EI) 490/492 (M)⁺.

***N*-(2-(4-(Benzo[*d*]thiazol-2-yl)piperazin-1-yl)-2-oxoethyl)-3-bromo-5-chlorothiophene-2-sulfonamide (5k).** From **k** (0.30 g). Yield: 0.51 g (96%); mp 175-177 °C. ¹H NMR (DMSO-*d*₆): δ 3.55 (brs, 8H, *H*_{piperazine}); 4.07 (s, 2H, CH₂C=O); 7.06-7.49 (m, 4H, *H*_{arom} + *H*_{thiophene}); 7.78 (d, *J* = 8 Hz, 1H, *H*_{arom}); 8.43 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ 41.3 (NHCH₂); 43.9, 44.6, 48.0, 48.2 (*C*_{piperazine}); 112.6 (*C*_{thioph}-Br), 119.2, 121.7, 121.9, 126.5, 130.9, 132.7, 134.4, 136.4 (*C*_{arom} + *C*_{thiophene}); 152.7 (*C*^{3a}_{benzothiazole}); 166.3 (C=O); 168.5 (C=N). Anal. calcd. for C₁₇H₁₆BrClN₄O₃S₃: C, 38.10; H, 3.01; N, 10.45. Found: C, 38.39; H, 3.22; N, 10.70. *m/z* (EI) 535/537 (M)⁺.

General procedure for preparation of 1-(4-(benzothiazol-2-yl)piperazinyl-1-yl)-2-(aryltio)ethanone (6a-j)

To a stirred solution of **4** (1.00 mmol) in DMF (10 mL) was added 60% NaH (1.0 mmol). After 15 min, the arylthiol (1.00 mmol) was added with stirring at 23 °C for 48 h. The solution was evaporated to dryness and the residue was extracted into CH₂Cl₂ (3 x 15 mL) and the organic solution was washed with water (2 x 20 mL), dried with Na₂SO₄ and concentrated under reduced pressure to obtain the product which purified using thin layer chromatography (CHCl₃-MeOH). The products were recrystallized from EtOH.

1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(phenylthio)ethanone (6a). From **a** (0.18 g). Yield: 0.31 g (83%); mp 215-217 °C. ¹H NMR (CDCl₃): δ 3.55-3.69 (m, 8H, *H*_{piperazine}), 4.07 (s, 2H, SCH₂), 7.09-7.77 (m, 9H, *H*_{arom}). ¹³C NMR (CDCl₃): δ 36.1 (SCH₂); 41.6, 45.5, 48.7, 49.1 (*C*_{piperazine}); 119.2, 121.7, 121.9, 126.5, 126.5, 129.0, 129.1, 129.4, 130.9 (*C*_{arom}); 136.1 (*C*_{arom-S}); 152.7 (*C*^{3a}_{benzothiazole}); 167.0 (C=N); 168.5 (C=O). Anal. calcd. for C₁₉H₁₉N₃OS₂: C, 61.67; H, 5.18; N, 11.37. Found: C, 61.37; H, 5.06; N, 11.17. *m/z* (EI) 369 (M)⁺.

1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(pyridin-2-ylthio)ethanone (6b). From **b** (0.18 g). Yield: 0.21 g (58%); mp 150-152 °C. ¹H NMR (CDCl₃): δ 3.63-3.98 (m, 8H, *H*_{piperazine}), 4.24 (s, 2H, SCH₂), 7.02- 8.44 (m, 8H, *H*_{arom}). ¹³C NMR (CDCl₃): δ 31.8 (SCH₂); 41.6, 45.6, 48.3, 48.6 (*C*_{piperazine}); 119.2, 120.0, 120.8, 122.1, 122.3, 126.4 (*C*_{arom} + *C*_{pyridine}); 136.5 *C*⁴_{pyridine}); 149.2 (*C*⁶_{pyridine}); 152.7 (*C*^{3a}_{benzothiazole}); 159.1 (*C*²_{pyridine-S}), 167.8 (C=N); 168.3 (C=O). Anal. calcd. for C₁₈H₁₈N₄OS₂: C, 58.35; H, 4.90; N, 15.12. Found: C, 58.32; H, 4.72; N, 14.92. *m/z* (EI) 370 (M)⁺.

1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(4-methylpyrimidin-2-ylthio)ethanone(6c). From **c** (0.19 g). Yield: 0.27 g (70%); mp 236-238 °C. ¹H NMR (CDCl₃): δ 2.48 (s, 3H, CH₃); 3.66-3.94 (m, 8H, *H*_{piperazine}), 4.18 (s, 2H, SCH₂), 6.88 (d, 1H, *J* = 7.3 Hz, *H*_{arom}); 7.25 (t, 1H, *J* = 7.0 Hz, *H*_{arom}); 7.48 (t, 1H, *J* = 7.4 Hz, *H*_{arom}); 7.70 (d, 2H, *J* = 7.2 Hz, *H*_{arom}); 8.40 (d, 1H, *J* = 7.5 Hz,). ¹³C NMR (CDCl₃): δ 24.2 (CH₃); 33.0 (SCH₂); 41.5, 45.5, 48.5, 48.9 (*C*_{piperazine}); 116.7 (*C*⁵_{pyrimidine}); 118.9, 121.0, 122.6, 126.7 (*C*_{arom}); 152.9 (*C*^{3a}_{benzothiazole}); 156.9 (*C*⁶_{pyrimidine}); 167.4 (C=N + *C*⁴_{pyrimidine-Me}); 168.0 (C=O); 170.0 (*C*²_{pyrimidine-S}). Anal. calcd. for C₁₈H₁₉N₅OS₂: C, 56.08; H, 4.97; N, 18.17. Found: C, 56.26; H, 4.76; N, 18.30. *m/z* (EI) 385 (M)⁺.

1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(5-methyl-1,3,4-thiadiazol-2-ylthio)ethanone (6d). From **d** (0.20 g). Yield: 0.30 g (77%); mp 176-178 °C. ¹H NMR (CDCl₃): δ 2.74 (s, 3H, CH₃); 3.68-3.90 (m, 8H, *H*_{piperazine}), 4.40 (s, 2H, SCH₂), 7.18 (t, 1H, *J* = 7.7 Hz, *H*_{arom}); 7.35 (t, 1H, *J* = 7.7 Hz, *H*_{arom}); 7.63 (d, 1H, *J* = 7.1 Hz, *H*_{arom}); 7.70 (d, 1H, *J* = 7.2 Hz, *H*_{arom}). ¹³C NMR (CDCl₃): δ 15.7 (CH₃); 36.0 (SCH₂); 41.6, 45.6, 48.7, 48.9 (*C*_{piperazine}); 118.9, 121.0, 122.8, 126.8, 130.9 (*C*_{arom}) 141.0 (*C*⁵_{thiophene}); 152.8 (*C*^{3a}_{benzothiazole}); (165.6 (*C*²_{thiophene-S}), 165.8 (C=N); 168.1 (C=O). Anal. calcd. for C₁₆H₁₇N₅OS₃: C, 49.08; H, 4.38; N, 17.89. Found: C, 49.36; H, 4.13; N, 18.00. *m/z* (EI) 391 (M)⁺.

2-(1*H*-1,2,3-Triazol-5-ylthio)-1-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)ethanone (6e). From **e** (0.17 g). Yield: 0.12 g (33%); mp 160-162 °C. ¹H NMR (CDCl₃): δ 3.16-3.63 (m, 8H, *H*_{piperazine}), 4.02 (s, 2H, SCH₂), 7.09 (t, 1H, *J* = 7.3 Hz); 7.29 (t, 1H, *J* = 7.3 Hz, *H*_{arom}); 7.47 (d, 1H, *J* = 8.0 Hz); 7.77 (d, 1H, *J* = 7.8 Hz, *H*_{arom}); 7.96 (s, 1H); 12.21 (brs., 1H, NH). ¹³C NMR (CDCl₃): δ 37.1 (SCH₂); 41.3, 45.2, 48.1, 49.4 (*C*_{piperazine}); 119.2, 121.9, 122.1, 124.0, 126.5, 130.4 (*C*_{arom} + *C*⁴_{triazole}); 139.5 (*C*⁵_{triazole-S}); 152.8 (*C*^{3a}_{benzothiazole}); 166.8 (C=N); 168.5 (C=O). Anal. calcd. for C₁₆H₁₆N₆OS₂: C, 49.98; H, 4.47; N, 23.31. Found: C, 49.80; H, 4.54; N, 23.20. *m/z* (EI) 360 (M)⁺.

1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(1-methyl-1*H*-imidazol-2-ylthio)ethanone (6f). From **f** (0.18 g). Yield: 0.23 g (62%); mp 120-122 °C. ¹H NMR (CDCl₃): δ 3.70 (s, 3H, CH₃); 3.63-3.82 (m, 8H, *H*_{piperazine}), 4.16 (s, 2H, SCH₂); 6.96-7.64 (m, 6H, *H*_{arom}). ¹³C NMR (CDCl₃): δ

33.5 (CH₃); 37.1 (SCH₂); 41.3, 45.2, 48.1, 48.3 (C_{piperazine}); 119.2, 121.9, 124.0, 126.5, 129.1, 130.9 (C_{arom} + C_{imidazole}); 139.5 (C²_{imidazole-S}); 152.8 (C^{3a}_{benzothiazole}); (C_{arom}⁺; 166.8 (C=N); 168.5 (C=O). Anal. calcd. for C₁₇H₁₉N₅OS₂: C, 54.67; H, 5.13; N, 18.75. Found: C, 54.65; H, 4.94; N, 18.70. *m/z* (EI) 373 (M)⁺.

1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(1-phenyl-1*H*-tetrazol-5-ylthio)ethanone (6g). From **g** (0.24 g). Yield: 0.38 g (86%); mp 195-197 °C. ¹H NMR (CDCl₃): δ 3.68-3.83 (m, 8H, *H*_{piperazine}), 4.51 (s, 2H, SCH₂); 7.15- 7.65 (m, 9H, *H*_{arom}). ¹³C NMR (CDCl₃): δ 37.1 (SCH₂); 41.7, 45.5, 48.2, 48.2 (C_{piperazine}); 119.4, 120.9, 122.2, 123.7, 126.4, 129.9, 130.3 133.5 (C_{arom}); 154.0 (C⁵_{tetrazole-S} + C^{3a}_{benzothiazole}); 165.1 (C=N); 168.1 (C=O). Anal. calcd. for C₂₀H₁₉N₇OS₂: C, 54.90; H, 3.83; N, 22.41. Found: C, 54.72; H, 3.88; N, 22.55. *m/z* (EI) 437 (M)⁺.

2-(Benzo[d]oxazol-2-ylthio)-1-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)ethanone (6h). From **h** (0.22 g). Yield: 0.25 g (62%); mp 132-134 °C. ¹H NMR (CDCl₃): δ 3.68-3.93 (m, 8H, *H*_{piperazine}), 4.40 (s, 2H, SCH₂), 7.15-7.70 (m, 8H, *H*_{arom}). ¹³C NMR (CDCl₃): δ 35.7 (SCH₂); 41.56, 45.5, 48.7, 49.1 (C_{piperazine}); 110.1 (C⁷_{oxazole}); 118.4, 118.8, 120.0, 120.6, 121.1, 123.0, 124.2, 124.5, 127.0 (C_{arom} + (C_{oxazole})); 141.6 (C^{3a}_{oxazole}); 152.1 (C^{3a}_{benzothiazole}); 164.0 (C²_{oxazole-S}); 168.0 (C=O + C=N). Anal. calcd. for C₂₀H₁₈N₄O₂S₂: C, 58.52; H, 4.42; N, 13.65. Found: C, 58.32; H, 4.70; N, 13.69. *m/z* (EI): 410 (M)⁺.

1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(benzo[d]thiazol-2-ylthio)ethanone (6i). From **i** (0.23 g). Yield: 0.24 g (57%); mp 140-142 °C. ¹H NMR (CDCl₃): δ 3.70-3.90 (m, 8H, *H*_{piperazine}), 4.45 (s, 2H, SCH₂), 7.28- 7.85 (m, 8H, *H*_{arom}). ¹³C NMR (CDCl₃): δ 35.6 (SCH₂); 41.5, 45.6, 48.9, 49.3 (C_{piperazine}); 118.7, 119.1, 120.1, 121.1, 121.2, 121.5, 123.1, 124.6, 126.3, 127.1; 135.1 (C_{arom} + C_{thiadiazole}); 152.7 (C^{3a}_{benzothiazole}); 164.2 (C²_{thiadiazole-S}), 166.4 (C=N); 168.0 (C=O). Anal. calcd. for C₂₀H₁₈N₄OS₃: C, 56.31; H, 4.25; N, 13.13. Found: C, 56.35; H, 4.06; N, 13.24. *m/z* (EI) 426 (M)⁺.

2-(1*H*-Benzo[d]imidazol-2-ylthio)-1-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)ethanone (6j). From **j** (0.22 g). Yield: 0.25 g (61%); mp 100-102 °C. ¹H NMR (CDCl₃): δ 3.61-3.83 (m, 8H, *H*_{piperazine}), 4.32 (s, 2H, SCH₂); 5.31 (brs., 1H, NH₂); 7.13-7.65 (m, 8H, *H*_{arom}). ¹³C NMR (CDCl₃): δ 34.4 (SCH₂); 41.7, 45.9, 47.9, 48.2 (C_{piperazine}); 119.5, 120.9, 121.0, 122.0, 122.1, 123.2, 125.4, 126.1, 126.2; 130.8 (C_{arom} + C_{benzimidazole}); 138.7 (C^{3a}_{benzimidazole} + C^{7a}_{benzimidazole}); 147.0 (C²_{benzimidazole-S}); 152.3 (C^{3a}_{benzothiazole}); 167.7 (C=N); 168.2 (C=O). Anal. calcd. for C₂₀H₁₉N₅OS₂: C, 58.66; H, 4.68; N, 17.10. Found: C, 58.72; H, 4.46; N, 17.09. *m/z* (EI) 409 (M)⁺.

General procedure for the preparation of *N*-(5-Ethoxybenzo[d]thiazol-2-yl)-aryl- and methylsulfonamides (**9b**, **9l-n**) and the 6-iodo analogue (**10**)

These compounds were prepared in a similar method for preparation of **5a-k**, by treatment of **7** and **8** (1.00 mmol) with aryl- and methylsulfonyl chlorides (**b**, **l-n**) (1.00 mmol). The products were recrystallized from EtOH.

***N*-(5-Ethoxybenzo[d]thiazol-2-yl)-4-methylbenzenesulfonamide (9b).** From **b** (0.19 g). Yield: 0.026 g (76%); mp 149-151 °C. ¹H NMR (CDCl₃): δ 1.30 (t, 3H, *J* = 7.1 Hz, OCH₂CH₃); 2.40

(s, 3H, CH₃); 4.03 (q, 2H, $J = 7.1$ Hz, OCH₂CH₃); 4.89 (brs., 1H, NH); 6.97 (dd, 1H, $J = 6.2$ Hz, 2.0 Hz, $H^6_{\text{benzothiazole}}$); 7.35-7.63 (m, 4H, H_{arom}); 7.87-8.01 (m, 2H, $H^4_{\text{benzothiazole}} + H^7_{\text{benzothiazole}}$). ¹³C NMR (CDCl₃): δ 14.5 (OCH₂CH₃); 21.2 (CH₃); 63.9 (OCH₂CH₃); 104.8 ($C^4_{\text{benzothiazole}}$); 114.5 ($C^6_{\text{benzothiazole}}$); 121.6, 122.4, 128.6, 130.4, 136.1, 137.9 (C_{arom}); 152.1 ($C^5_{\text{benzothiazole}}$); 149.3 ($C^{3a}_{\text{benzothiazole}}$); 174.1 (C=N). Anal. calcd. for C₁₆H₁₆N₂O₃S₂: C, 55.15; H, 4.63; N, 8.04. Found: C, 54.92; H, 4.58; N, 7.87. m/z (FAB) 349 (M+H)⁺.

***N*-(5-Ethoxybenzo[*d*]thiazol-2-yl)-2,4-nitrobenzenesulfonamide (9l).** From **l** (0.27 g). Yield: 0.28 g (67%); mp 193-194 °C. ¹H NMR (CDCl₃): δ 1.31 (t, 3H, $J = 7.0$ Hz, OCH₂CH₃); 4.08 (q, 2H, $J = 7.0$ Hz, OCH₂CH₃); 7.00 (dd, 1H, $J = 6.3$ Hz, 2.1 Hz, $H^6_{\text{benzothiazole}}$); 7.88-8.05 (m, 2H, $H^4_{\text{benzothiazole}} + H^7_{\text{benzothiazole}}$); 8.96-8.39 (m, 3H, H_{arom}). ¹³C NMR (CDCl₃): δ 14.6 (OCH₂CH₃); 64.1 (OCH₂CH₃); 105.2 ($C^4_{\text{benzothiazole}}$); 114.1 ($C^6_{\text{benzothiazole}} + C^3_{\text{arom}}$); 121.2, 122.5, 129.3, 130.6, 140.1 (C_{arom}); 148.0 ($C^{3a}_{\text{benzothiazole}} + C^2_{\text{arom-NO}_2}$); 152.1 ($C^5_{\text{benzothiazole}} + C^4_{\text{arom-NO}_2}$); 174.3 (C=N). Anal. Calcd. For C₁₅H₁₂N₄O₇S₂: C, 42.45; H, 2.85; N, 13.20. Found: C, 42.23; H, 2.69; N, 12.97. m/z (FAB) 425 (M+H)⁺.

***N*-(5-Ethoxybenzo[*d*]thiazol-2-yl)-1-benzylsulfonamide (9m).** From **m** (0.19 g). Yield: 0.26 g (75%); mp 202-203 °C. ¹H NMR (CDCl₃): δ 1.30 (t, 3H, $J = 7.2$ Hz, OCH₂CH₃); 4.10 (q, 2H, $J = 7.2$ Hz, OCH₂CH₃); 4.30 (s, 2H, CH₂Ph); 6.97 (dd, 1H, $J = 6.4$ Hz, 2.0 Hz, $H^6_{\text{benzothiazole}}$); 7.23-7.37 (m, 5H, CH₂Ph); 7.85-7.98 (m, 2H, $H^4_{\text{benzothiazole}} + H^7_{\text{benzothiazole}}$). ¹³C NMR (CDCl₃): δ 14.7 (OCH₂CH₃); 64.2 (OCH₂CH₃); 65.1 (CH₂Ph); 104.9 ($C^4_{\text{benzothiazole}}$); 113.8 ($C^6_{\text{benzothiazole}}$); 121.0, 122.3, 129.0, 128.4, 130.8, 133.0 (C_{arom}); 148.5 ($C^{3a}_{\text{benzothiazole}}$); 152.4 ($C^5_{\text{benzothiazole}}$); 173.9 (C=N). Anal. Calcd. For C₁₆H₁₆N₂O₃S₂: C, 55.15; H, 4.63; N, 8.04. Found: C, 54.90; H, 4.53; N, 7.85. m/z (FAB) 349 (M+H)⁺.

***N*-(5-Ethoxybenzo[*d*]thiazol-2-yl)-methanesulfonamide (9n).** From **n** (0.12 g). Yield: 0.17 g (60%); mp 155-156 °C. ¹H NMR (CDCl₃): δ 1.29 (t, 3H, $J = 7.0$ Hz, OCH₂CH₃); 2.92 (s, 3H, SO₂Me); 4.07 (q, 2H, $J = 7.0$ Hz, OCH₂CH₃); 4.30 (s, 2H, CH₂Ph); 6.99 (dd, 1H, $J = 6.5$ Hz, 2.1 Hz, $H^6_{\text{benzothiazole}}$); 7.88 (m, 1H, $H^7_{\text{benzothiazole}}$); 8.02 (d, 1H, $J = 6.5$ Hz, $H^4_{\text{benzothiazole}}$). ¹³C NMR (CDCl₃): δ 14.3 (OCH₂CH₃); 64.4 (OCH₂CH₃); 42.2 (SO₂Me); 105.1 ($C^4_{\text{benzothiazole}}$); 113.9 ($C^6_{\text{benzothiazole}}$); 121.3, ($C^7_{\text{benzothiazole}} + C^{7a}_{\text{benzothiazole}}$); 149.1 ($C^{3a}_{\text{benzothiazole}}$); 152.6 ($C^5_{\text{benzothiazole}}$); 174.2 (C=N). Anal. Calcd. For C₁₀H₁₂N₂O₃S₂: C, 44.10; H, 4.44; N, 10.29. Found: C, 43.89; H, 4.37; N, 10.03. m/z (FAB) 299 (M+Na)⁺.

***N*-(6-Iodobenzo[*d*]thiazol-2-yl)-2,4-nitrobenzenesulfonamide (10).** From **l** (0.27 g). Yield: 0.035 g (70%); mp 191-192 °C. ¹H NMR (CDCl₃): δ 7.50 (d, 1H, $J = 6.6$ Hz, $H^4_{\text{benzothiazole}}$); 9.01-7.82 (m, 5H, H_{arom}). ¹³C NMR (CDCl₃): δ 90.8 ($C^6_{\text{benzothiazole}}$); 114.3 ($C^3_{\text{arom-NO}_2}$); 122.8, 129.2, 130.1, 131.1 (C_{arom}); 140.0 ($C^1_{\text{arom-NO}_2}$); 148.0 ($C^2_{\text{arom-NO}_2}$); 151.8 ($C^{3a}_{\text{benzothiazole}} + C^4_{\text{arom-NO}_2}$); 174.0 (C=N). Anal. Calcd. For C₁₃H₇IN₄O₆S₂: C, 30.84; H, 1.39; N, 11.07. Found: C, 30.62; H, 1.30; N, 10.91. m/z (FAB) 528/530 (M+Na)⁺.

Cytotoxicity assays

Cell cultures were seeded at 1x10⁵ cells/ml in 96 multiwell plates in specific media supplemented with 10% FCS and antibiotics and incubated at 37 °C in a humidified CO₂ (5%)

atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability was determined after 96 hrs at 37 °C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method.²⁶

Compounds were dissolved in DMSO at 100 mM and then diluted into culture medium.

References

1. Bradshaw, T. D.; Chua, M. S.; Browne, H. L.; Trapani, V.; Suasville, E. A.; Stevens, M. F. G. *Br. J. Cancer* **2002**, *86*, 1348.
2. Hutchinson, I.; Jennings, S. A.; Vishnuvajjala, B. R.; Westwell, A. D.; Stevens, M. F. G. *J. Med. Chem.* **2002**, *45*, 744.
3. Leong, C. O.; Suggitt, M.; Swaine, D. J.; Bibby, M. C.; Stevens, M. F. G.; Bradshaw, T. D. *Mol. Cancer Ther.* **2004**, *3*, 1565.
4. El-Sherbeny, M. A. *Arzneim. Forsch.* **2000**, *50*, 848.
5. Shi, D.; Bradshaw, T. D.; Wrigley, S.; McCall, C. J.; Lelieveld, P.; Fichtner, I.; Stevens, M. F. G. *J. Med. Chem.* **1996**, *37*, 3375.
6. Bradshaw, T. D.; Wrigley, S.; Schultz, R. J.; Paull, K. D.; Stevens, M. F. G. *Br. J. Cancer* **1998**, *77*, 745.
7. Bradshaw, T. D.; Shi, D. F.; Schultz, R. J.; Paull, K. D.; Kelland, L.; Wilson, A.; Garner, C.; Fiebig, H. H.; Wrigley, S.; Stevens, M. F. G. *Br. J. Cancer* **1998**, *77*, 421.
8. Kashiya, E.; Hutchinson, I.; Chua, M.-S.; Stinson, S. F.; Phillips, L. R.; Kuar, G.; Sausville, E. A.; Bradshaw, T. D.; Westwell, A. D.; Stevens, M. F. G. *J. Med. Chem.* **1999**, *42*, 4172, references therein cited.
9. Trapani, G.; Franco, M.; Latrofa, A.; Reho, A.; Liso, G. *Eur. J. Pharm. Sci.* **2001**, *14*, 209.
10. Srimanth, K.; Rao, V. R.; Krishna, D. R. *Arzneim.-Forsch.* **2002**, *52*, 388.
11. Watson, K. J.; Anderson, D. R.; Nguyen, S. T. *Macromolecules* **2001**, *34*, 3507.
12. Caleta, I.; Grdisa, M.; Mrvos-Sermek, D.; Cetina, M.; Tralić-Kulenović, V. K.; Pavelić, G.; Karminski-Zamola, G. *Farmaco* **2004**, *59*, 297.
13. Loaiza-Pérez, A. I.; Trapni, V.; Patel, V.; Hose, C.; Singh, S. S.; Trepel, J. B.; Stevens, M. F. G.; Bradshaw, T. D.; Sauville, E. A. *Mol. Pharmacol.* **2002**, *61*, 13.
14. Monks, A.; Harris, E.; Hose, C.; Connelly, J.; Sausville, E. A. *J. Med. Chem.* **2006**, *49*, 179.
15. Bradshaw, T. D.; Bibby, M. C.; Double, J. A.; Fichtner, I.; Cooper, P. A.; Alley, M. C.; Donhue, S.; Stinson, S. F.; Tomaszewski, J. E.; Suaville, E. A.; Stevens, M. F. G. *Mol. Cancer Therap.* **2002**, *1*, 239.
16. Trapni, V.; Patel, V.; Leong, C-O; Ciolino, H. P.; Yeh, G. C.; Hose, C.; Trepel, J. B.; Stevens, M. F. G.; Sauville, E. A.; Loaiza-Pérez, A. I. *Br. J. Cancer* **2003**, *88*, 599.
17. Mortimer, C. G.; Wells, G.; Grochard, J.-P., Stone, E. L.; Bradshaw, T. D.; Stevens, M. F. G.; Westwell, A. D. *J. Med. Chem.* **2006**, *49*, 179.
18. Wells, G.; Berry, J. M.; Bradshaw, T. D.; Burger, A. M.; Seaton, A.; Wang, B.; Westwell, A.

- D.; Stevens, M. F. G. *J. Med. Chem.* **2003**, *46*, 532.
19. Bradshaw, T. D.; Westwell, A. D. *Curr. Med. Chem.* **2004**, *11*, 1241.
20. Fichtner, I.; Monks, A.; Hose, C.; Stevens, M. F. G.; Bradshaw, T. D. *Breast Cancer Res. Treat.* **2004**, *87*, 97.
21. Yoshida, M.; Haykawa, I.; Hayshi, N.; Agatsuma, Kurakata, S. K.; Sugano, Y. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3328.
22. Racane, L.; Tralic-Kulenovic, V.; Fiser-Jakic, L.; Boykin, D. W.; Karminski-Zamola, G. *Heterocycles* **2001**, *55*, 2085.
23. Al-Soud, Y. A.; Al-Sa'doni, H. H.; Amjaour, H. A. S.; Salih, K. S. M., Mubarak, M. S.; Al-Masoudi; N. A. and Jaber, I. H. *Z. Naturforsch.* **2008**, *63b*, 83.
24. Walczynski, K.; Guryn, R.; Zuiderveld, O. P.; Timmerman, H. *Arch. Pharm. Pharm. Med. Chem.* **1999**, *332*, 389.
25. Hose, C. D.; Hollingshead, M.; Sausville, E. A.; Monks, A. *Mol. Cancer Ther.* **2003**, *2*, 1265.
26. Pauwles, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijin, P.; Desmyster, J.; De Clercq, E. *J. Virol. Methods* **1988**, *20*, 309.